The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
anybody interested in RELX ? goldman sachs says buy and targets £21.78
Wrong company - RELX is this company - https://www.relx.com/
I saw this on the bbc and started looking deeper - the maths/science looks interesting http://www.bbc.co.uk/news/science-environment-43732035
Is anyone aware of why this share price is sliding downwards?
£34bn information and analytics business Relx, formerly called Reed Elsevier is one to buy and hold for a long time as the company’s management has successfully repositioned the business to focus on faster growing areas. It has shifted from a print business to technology led data and analytics. Relx is a well invested, well managed, cash generative global business with market leading positions. Relx’s subscription based model provides good visibility of future revenues. It can continue delivering revenue growth, margin expansion, "high single digit" earnings per share growth, and increase its cash returns over time. Expect further progress as it benefits from new product development and international expansion, including into emerging markets.
Insider - Eric Engstrom recently sold 178,799 shares. Is this due to SP reaching record highs. Due for a price drop soon. Time to take profits - Too good to be true.
RECOMMENDATION SELL TARGET 1085 The Major trend of RELX PLC it is showing strength for selling .If it breaks the support level then one can initiate the selling position in the stock. If it breaks the level of 1096 then it can test support level for the target of 1085 with the stop loss of 1106 CHART FORMATION:- Stock is trading in a range and trading near the trend-line. Breaking the support line will lead to downside movement. Stock is trading below the 50 DMA with negative bias. INDICATORS:- RSI is trading near to 38.22 level with negative bias, in upcoming session downside movement is expected. MACD and Signal line is sustaining below the zero level line. Skype tayal.smith1
REL Technicaly looking very bullish here the chart...... http://chartattack.webs.com/reed%20else.JPG
Now live 943.50p Time to go SHORT or sell out.
QPP should be now be worried IMO http://www.cityam.com/article/1400632392/reed-elsevier-buys-wunelli-beef-its-telematics-business
Last year, from 8th Feb, this share rose eight consecutive weeks in a row! Wow! Reed has also been doing a lot of buying its own shares. Looks like a very good bet and a time to buy before finals and the raise sets in. That's if the share develops in a similar pattern to last year! Don't see why it shouldn't. Haven't read of any problems. Good luck to all investors in Reed.
on the rise and this share looks like a share with potential to rise more ,with a lot of shares traded today , will be watching this share price ,will also be watching amerisure today , rel to me looks to be a share with potential
21 May Reed Elsevier PLC REL Deutsche Bank Buy 0.00 767.50 790.00 820.00 Reiterates SP Target 820p.
REL SP broken through ceiling of a downward trend channel looks very positive for the future, Targeting 300p as first point of call in the turnaround here. <img src="http://mycharts1.webs.com/reid%20Else.JPG">
Reed Elsevier: UBS revises target price from 770p to 790p, its buy recommendation is unaltered.
Reed Elsevier: HSBC raises target price from 675p to 720p, while downgrading to neutral.
Reed Elsevier: Deutsche Bank shifts target price from 730p to 740p and reiterates a buy recommendation.
Reed Elsevier: Investec increases target price from 735p to 780p and still recommends to buy.
Reed Elsevier: Deutsche Bank raises target price from 690p to 730p; buy rating unchanged.
Reed Elsevier: Nomura raises target price from 700p to 750p and keeps its buy recommendation.
Reed Elsevier: Jefferies keeps buy rating and 635p target.
Positive Points: Trading for the full year remains in line with expectations. A focus on improving operational efficiency is ongoing. The board expects to continue its transformation of the business through organic development, along with disposing of businesses that no longer fit its strategy. Based on transactions either completed or well progressed so far this year, management raised the amount that will be deployed on share buybacks this year to £250 million. A concentration on pushing new products into adjacent markets and geographies continues to be pursued. A progressive dividend policy is being followed. A 6% increase to the half year dividend was previously announced.
Negative Points: The company reported underlying revenue growth of 4%, down from the 5% recorded as of the half year stage. Reed Elsevier's client base is primarily businesses, many of whom continue to cut or restrain costs. Competition within the sector remains intense. The group would be exposed to any potential political change on funding of research papers or academic publishing.
Financial Highlights: Underlying revenue growth of 4% reported. Management reported that the group's financial position remains strong.
Third quarter update: Reed Elsevier highlights in line trading. The statement saw management highlighting in line trading, with guidance for the full year being reaffirmed - the share price was marginally higher (+0.3%) in midday trading. Underlying revenue growth of 4% was reported, with all five business areas contributing. In August, its Elsevier division was reorganised, combining the leadership of Science & Technology and Health Sciences. Underlying revenue growth of 2% was reported year to date. Its LexisNexis Risk Solutions business enjoyed demand for risk management tools across financial institutions, with underlying revenues up 6%, whilst the Exhibitions division saw strong growth in the US and Emerging Markets - underlying revenues rose by 15% over the year to date. In all, despite concerns for the economic outlook, the group's transformation moving online and disposing of businesses that no longer fit management's strategy and using proceeds to buy-back shares is seen as positive,